

Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally



Shifting priorities have created a backlog of pharmaceuticals awaiting testing, prompting the pharmaceutical industry to turn to innovative solutions to bring products to market. Effectively dealing with this challenge involves ensuring the timely evaluation of these drugs for both safety and efficacy in a cost-effective manner without sacrificing the quality of test results. To cope with the increased demand, many organizations are leveraging humanized mouse models to provide mission-critical data in the early stages of the drug development lifecycle. [The global humanized mouse and rat model market is estimated to have reached \\$259 million in 2023](#) and is expected to reach \$349 million by 2028 (growing at a CAGR of 6.2% from 2023 to 2028).

Founded in 2007, Yecuris Corporation (“Yecuris”) provides liver-humanized mice to its global customer base across a wide range of

application areas; such as cell and gene therapy, NASH/NAFLD, viral hepatitis, malaria, and cardiovascular disease, among others. Their clients and collaborators include world-renowned academic research institutions, Big Pharma and Biotech, as well as many of the most popular earlier-stage VC funded companies. Yecuris stands out as a premier provider of preclinical services, with an impressive list of partners using its patent-protected FRG® technology. Their unique offering made them a clear fit within Janvier Group’s (“Janvier”) already robust portfolio.

Crosstree’s unique knowledge of the global preclinical market and current trends helped Yecuris identify Janvier as the ideal strategic fit for the business. The resulting collaboration will enable the combined company to accelerate growth, expand service offerings, and increase its reach globally.

Crosstree's granular knowledge of the preclinical pharma services industry allows us to generate innovative outcomes

ABOUT YECURIS



Founded in 2007 as a start-up company based on technology developed in the laboratory of Dr. Markus Grompe at Oregon Health and Science University, Yecuris has grown its proprietary FRG liver-humanized mouse model into a globally recognized name. Yecuris' products and services help biotechnology and pharmaceutical companies active in the fields of Gene Therapy, Infectious Disease, Metabolic Disease, and Liver Disease develop next-generation medicines to treat human disease. Our singular purpose is to deliver actionable results that clients can depend on to make critical decisions in their drug development programs.

ABOUT THE JANVIER GROUP



Founded in 1960, the Janvier Group is one of the world leaders, recognized for the quality of its research models and associated services which are delivered in compliance with the standards among the highest in the world market. Historically focused on research models with its subsidiary Janvier Labs which relies on the largest and most modern production site in Europe, Janvier Group is now an established player in preclinical services with its subsidiaries in France and internationally. Today, the Janvier Group operates throughout Europe and internationally with more than 3,500 customers.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JEFF ELLIS

Co-Founder & Managing Director

jeff.ellis@crosstrecapital.com

813-774-4753